Masitinib not checked

AB Science · AB1010

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
14 in total · 5 in the EU

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
Main trialPhase 3
“The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).”In the company’s words, NCT03127267 on ClinicalTrials.gov
Other names
AB1010

Other drugs for Amyotrophic Lateral Sclerosis

All 48 drugs for Amyotrophic Lateral Sclerosis

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2027 Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Phase 3Not yet recruiting 31 Dec 2028 Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Phase 3Not yet recruiting Dec 2028 Masitinib in Patients With Mild Alzheimer's Disease
Phase 3Terminated Jul 2018 Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Phase 3Completed Nov 2019 Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
Phase 3Completed 15 Dec 2020 Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Phase 3Completed Dec 2020 Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Phase 3Unknown Dec 2024 Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Phase 3Suspended Dec 2028 Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
Phase 2/3Completed 5 Dec 2016 Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Phase 2Unknown Dec 2023 Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Phase 2Unknown Dec 2023 Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Phase 2Unknown 31 Dec 2024 Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Phase 3Ended not given A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Masitinib

Following is part of Solo: you see every change to Masitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in